# A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

> **NCT05622708** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 240 (actual)

## Conditions studied

- Non-radiographic Axial Spondyloarthritis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo
- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT05622708
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-28
- **Primary completion:** 2028-04-19
- **Final completion:** 2028-06-13
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622708, "A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05622708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*